Impact Biomedical Announces Reverse Stock Split & Merger Update

Health

Reverse Stock Split
IPO:
Nov 18, 2026
Industry:
PHARMACEUTICAL PREPARATIONS
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
Impact Biomedical Announces 1 for 12.62 Reverse Stock Split and Corrects Merger Exchange Ratio with Zoar Limited
Houston, Texas, USA - Impact Biomedical Inc. (NYSE: IBO) announced that its Board of Directors has approved a 1 for 12.62 reverse stock split of its issued and outstanding common stock. The corporate action will become effective at 12:01 a.m., Eastern Time, on September 23, 2026, with the common stock continuing to trade on the NYSE American Exchange under the ticker symbol IBO.
... Read on — Members only
About Zoar Ltd
Zoar Limited is a global pharmaceutical company focused on the development and manufacturing of active pharmaceutical ingredients and orphan drugs and provides contract development and manufacturing services to pharmaceutical and biotechnology companies worldwide. To date, Zoar Limited has shipped more than 85 pharmaceutical products to customers in 35 countries.

















